Free tool
FAERS Monitor: Climara Pro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021258 or its brand name (Climara Pro, Estradiol, Levonorgestrel). Reports on generic versions are filed under their own applications.
Reports
2,062
Serious
253
12% of reports
Hospitalization
14
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product adhesion issue668
- product physical issue348
- device adhesion issue268
- wrong technique in product usage process265
- hot flush230
- application site rash194
- drug ineffective157
- product quality issue139
- application site pruritus110
- application site erythema102
- application site irritation94
- device breakage94
- drug dose omission87
- wrong technique in device usage process76
- vaginal haemorrhage73
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 13 |
| 2008 | 104 |
| 2009 | 106 |
| 2010 | 110 |
| 2011 | 82 |
| 2012 | 105 |
| 2013 | 67 |
| 2014 | 88 |
| 2015 | 97 |
| 2016 | 118 |
| 2017 | 239 |
| 2018 | 159 |
| 2019 | 101 |
| 2020 | 95 |
| 2021 | 89 |
| 2022 | 71 |
| 2023 | 90 |
| 2024 | 96 |
| 2025 | 124 |
| 2026 | 101 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,097 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product adhesion issueSignal | 668 | 194.3 | 182.4 | 126,093 |
| device adhesion issueSignal | 268 | 181.3 | 162.0 | 47,079 |
| product physical issueSignal | 348 | 179.0 | 162.5 | 60,428 |
| application site rashSignal | 194 | 145.9 | 127.5 | 27,409 |
| application site irritationSignal | 94 | 77.6 | 63.7 | 6,986 |
| application site pruritusSignal | 110 | 49.7 | 41.4 | 5,180 |
| application site erythemaSignal | 102 | 39.8 | 33.0 | 3,814 |
| hot flushSignal | 230 | 31.2 | 27.6 | 6,701 |
| device breakageSignal | 94 | 23.7 | 19.4 | 2,018 |
| vaginal haemorrhageSignal | 73 | 17.2 | 13.7 | 1,097 |
| wrong technique in device usage processSignal | 76 | 16.6 | 13.3 | 1,101 |
| wrong technique in product usage processSignal | 265 | 13.4 | 11.9 | 3,042 |
| product quality issueSignal | 139 | 10.4 | 8.9 | 1,185 |
| drug dose omissionSignal | 87 | 5.4 | 4.4 | 307 |
| drug ineffective | 157 | 1.2 | 1.0 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.